NCT05145309View on ClinicalTrials.gov

Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2031

Conditions
Hypertension
Interventions
DRUG

KMgCit

Supplement that provide K, Mg, and citrate

DRUG

Placebo

Power with identical appearance to KMgCit

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT05145309 - Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans | Biotech Hunter | Biotech Hunter